Ascites in Adults

1. Clinical Overview

What is Ascites?

Ascites is the pathological accumulation of fluid within the peritoneal cavity. It represents a cardinal manifestation of decompensated cirrhosis and portal hypertension, though diverse aetiologies including malignancy, cardiac failure, and nephrotic syndrome must be considered. [1] The development of ascites in cirrhotic patients marks a critical inflection point: 2-year mortality approximates 50%, necessitating prompt evaluation for liver transplantation. [2]

Cirrhosis with portal hypertension accounts for approximately 75-85% of ascites cases in Western populations. [3] The serum-ascites albumin gradient (SAAG) serves as the cornerstone diagnostic tool, reliably distinguishing portal hypertensive causes (SAAG ≥11 g/L) from non-portal hypertensive aetiologies (SAAG less than 11 g/L) with 97% accuracy. [4] Management hinges upon sodium restriction, aldosterone antagonism with spironolactone, and judicious use of loop diuretics. Refractory ascites demands consideration of serial large-volume paracentesis with albumin replacement, transjugular intrahepatic portosystemic shunt (TIPS), or liver transplantation. [5]

Spontaneous bacterial peritonitis (SBP) constitutes a life-threatening complication affecting 10-30% of cirrhotic patients with ascites annually. [6] Diagnostic paracentesis must be performed liberally in any cirrhotic patient presenting with fever, abdominal pain, encephalopathy, or unexplained clinical deterioration. Prompt recognition and empirical third-generation cephalosporin therapy significantly reduce mortality. [7]

Key Facts

• Prevalence in cirrhosis: Approximately 60% of compensated cirrhotic patients develop ascites within 10 years of diagnosis. [2]
• Most common cause: Cirrhosis accounts for 75-85% of cases; malignancy 10%, cardiac failure 3%. [3]
• SAAG ≥11 g/L: Indicates portal hypertension (cirrhosis, cardiac ascites, Budd-Chiari syndrome, portal vein thrombosis).
• SAAG less than 11 g/L: Suggests non-portal causes (peritoneal carcinomatosis, tuberculous peritonitis, pancreatic ascites, nephrotic syndrome).
• Mortality: Two-year survival of cirrhotic patients following first ascites development is approximately 50%. [2]
• First-line therapy: Sodium restriction (less than 2 g/day) plus spironolactone 100 mg daily, with or without furosemide 40 mg daily. [5]
• Refractory ascites: Occurs in approximately 10% of patients; defined as ascites unresponsive to maximum diuretic therapy or recurrent despite compliance. [8]

Clinical Pearls

The SAAG Revolution: SAAG (serum albumin - ascitic fluid albumin) replaced the outdated exudate/transudate classification in the 1990s. SAAG ≥11 g/L correlates with portal hypertension (portal pressure > 12 mmHg) with 97% accuracy, regardless of infection or malignancy. [4] This single calculation dramatically simplifies the diagnostic approach to ascites.

Tap Early, Tap Often: Every cirrhotic patient with ascites admitted to hospital should undergo diagnostic paracentesis within 24 hours, regardless of symptoms. SBP may be clinically silent in up to 30% of cases. [6,7] The procedure is safe (haemorrhage risk less than 1%), even with INR > 2 or platelets > 40,000/μL. [9]

The 100:40 Ratio: Spironolactone and furosemide should be initiated in a 100:40 mg ratio (e.g., spironolactone 100 mg + furosemide 40 mg daily) to maintain normokalemia while achieving natriuresis. Escalate doses proportionally (200:80, 300:120, maximum 400:160) until adequate response or adverse effects. [5]

Albumin is Not Just Volume: Albumin replacement after large-volume paracentesis (8 g per litre removed if > 5 L drained) prevents post-paracentesis circulatory dysfunction, reducing mortality and hepatorenal syndrome incidence. [10] This is a specific pharmacological effect, not merely volume expansion.

Why This Matters Clinically

Ascites signifies transition from compensated to decompensated cirrhosis, fundamentally altering prognosis and management strategy. Once ascites develops, median survival without liver transplantation is approximately 2 years. [2] MELD (Model for End-Stage Liver Disease) scoring and transplant evaluation become imperative.

Early identification of refractory ascites, hepatorenal syndrome, and SBP can prevent progressive deterioration. Conversely, over-diuresis precipitates acute kidney injury and hepatorenal syndrome, further worsening outcomes. The balance between adequate decongestion and preserving renal perfusion requires meticulous clinical judgment and regular biochemical monitoring.

---

2. Epidemiology

Incidence & Prevalence

Ascites represents the most common complication of cirrhosis and the most frequent reason for hospital admission in this population. [1] Approximately 60% of patients with compensated cirrhosis develop ascites within 10 years of diagnosis. [2] Once ascites appears, the 1-year probability of developing a second major decompensation event (variceal bleeding, encephalopathy, SBP) exceeds 60%. [11]

Demographics

Causes of Ascites by SAAG

The SAAG-based classification system fundamentally organizes ascites aetiology by pathophysiological mechanism: portal hypertension versus other causes. [4]

Mixed Ascites: Approximately 5% of cirrhotic patients with ascites develop superimposed peritoneal carcinomatosis (hepatocellular carcinoma with peritoneal seeding, or unrelated malignancy). SAAG remains ≥11 g/L (portal hypertension persists), but cytology may be positive. [13]

---

3. Aetiology & Pathophysiology

Pathophysiological Mechanisms by SAAG Category

Portal Hypertensive Ascites (SAAG ≥11 g/L)

The formation of ascites in cirrhosis requires both portal hypertension (hepatic venous pressure gradient [HVPG] ≥12 mmHg) and systemic circulatory dysfunction. [1,14]

Step 1: Portal Hypertension

• Cirrhosis increases intrahepatic vascular resistance through:
  • "Structural component: Fibrosis, sinusoidal capillarization, vascular remodelling, regenerative nodules compressing hepatic venules."
  • "Dynamic component: Endothelial dysfunction with reduced nitric oxide (NO) production, increased endothelin-1 (ET-1), leading to hepatic vasoconstriction. [14]"
• Portal pressure rises; clinically significant portal hypertension defined as HVPG ≥10 mmHg.
• HVPG ≥12 mmHg threshold required for ascites formation. [14]

Step 2: Splanchnic Vasodilation ("Peripheral Arterial Vasodilation Hypothesis")

• Portal hypertension causes splanchnic arterial vasodilation via:
  • Increased splanchnic NO production (bacterial translocation, endotoxemia stimulate inducible NO synthase). [15]
  • "Accumulation of vasodilators: glucagon, substance P, prostacyclin, endocannabinoids."
• Systemic arterial vasodilation leads to relative hypovolaemia despite total body sodium and water excess. [15]

Step 3: Neurohumoral Activation

• Compensatory activation of:
  • "Renin-angiotensin-aldosterone system (RAAS): Aldosterone promotes renal sodium reabsorption (distal tubule)."
  • "Sympathetic nervous system: Renal vasoconstriction, further sodium retention."
  • "Antidiuretic hormone (ADH): Free water retention, dilutional hyponatraemia. [15]"
• Net effect: Avid renal sodium and water retention.

Step 4: Ascites Formation

• Elevated sinusoidal hydrostatic pressure (portal hypertension) exceeds oncotic pressure (hypoalbuminaemia from hepatic synthetic dysfunction).
• Fluid transudates across hepatic sinusoids into peritoneal cavity.
• Hepatic lymph production increases 20-fold; overwhelms thoracic duct drainage capacity. [16]
• Persistent sodium retention replenishes intravascular volume, perpetuating cycle.

Exam Detail: Molecular Pathophysiology: Nitric Oxide and Splanchnic Vasodilation

Bacterial translocation from the gut (due to portal hypertensive enteropathy and increased intestinal permeability) exposes the mesenteric circulation to endotoxin (lipopolysaccharide, LPS). LPS activates Toll-like receptor 4 (TLR4) on endothelial cells and macrophages, inducing inducible nitric oxide synthase (iNOS) expression. [15]

NO diffuses into vascular smooth muscle, activating soluble guanylate cyclase (sGC), increasing cyclic GMP (cGMP), and causing vasodilation. This splanchnic vasodilation is the primary driver of systemic circulatory dysfunction.

Hepatorenal Syndrome Pathophysiology

Progressive splanchnic vasodilation and worsening effective arterial hypovolaemia eventually exceed compensatory capacity. Extreme renal vasoconstriction (RAAS, sympathetic activation) causes functional acute kidney injury without intrinsic renal pathology—hepatorenal syndrome (HRS). HRS-AKI (previously HRS Type 1) is rapidly progressive; HRS-NAKI (previously HRS Type 2) is slower and associated with refractory ascites. [17]

Non-Portal Hypertensive Ascites (SAAG less than 11 g/L)

Peritoneal Carcinomatosis

• Malignant cells seed peritoneal surface (ovarian, gastric, pancreatic, colorectal, breast, lung cancers; mesothelioma).
• Tumour deposits increase peritoneal permeability and secrete vascular endothelial growth factor (VEGF), increasing capillary leakiness. [18]
• Lymphatic obstruction impairs fluid reabsorption.

Tuberculous Peritonitis

• Mycobacterium tuberculosis seeds peritoneum (haematogenous spread, direct extension from bowel TB, reactivation of latent foci).
• Granulomatous inflammation increases peritoneal exudation.
• Diagnosis requires ascitic fluid adenosine deaminase (ADA) assay (sensitivity ~95% if ADA > 39 IU/L) or peritoneal biopsy. [19]

Pancreatic Ascites

• Pancreatic duct disruption (chronic pancreatitis, trauma, post-ERCP) leaks enzyme-rich fluid into peritoneum.
• Ascitic fluid amylase markedly elevated (often > 1000 IU/L; serum amylase may be normal). [20]

Nephrotic Syndrome

• Severe hypoalbuminaemia (less than 20 g/L) reduces oncotic pressure; anasarca develops (ascites, peripheral oedema, pleural effusions).
• Diagnostic: Urine protein > 3.5 g/24 hours, serum albumin less than 30 g/L.

---

4. Clinical Presentation

Symptoms

Ascites itself is often asymptomatic until moderate or severe volume accumulates. Symptoms primarily reflect mechanical effects and underlying disease.

Common Symptoms:

• Abdominal distension (progressive, diffuse): Cardinal symptom; noticed by patients as increasing belt size or difficulty fastening trousers.
• Weight gain (rapid, non-physiological): Fluid accumulation; 1 litre ascites ≈ 1 kg weight gain.
• Early satiety, nausea, dyspepsia: Ascites displaces stomach, reduces gastric capacity.
• Dyspnoea (worse when supine): Diaphragmatic elevation reduces lung volumes; may cause orthopnoea.
• Ankle and leg swelling (peripheral oedema): Often accompanies ascites in cirrhosis (hypoalbuminaemia, venous insufficiency).
• Reduced mobility: Tense ascites limits movement; sarcopenia common in cirrhosis.

Symptoms Suggesting Complications:

• Fever, abdominal pain, tenderness: Suspect SBP. [6,7]
• Confusion, altered mental status: Hepatic encephalopathy (SBP may precipitate decompensation).
• Oliguria, reduced urine output: Hepatorenal syndrome or over-diuresis.
• Dyspnoea at rest, hypoxia: Tense ascites, hepatic hydrothorax (pleural effusion communicating via diaphragmatic defect), or hepatopulmonary syndrome.

Symptoms by Underlying Cause:

• Cirrhosis: Jaundice, pruritus, confusion (encephalopathy), haematemesis or melaena (variceal bleeding).
• Malignancy: Weight loss (cachexia, not fluid), night sweats, abdominal pain (peritoneal involvement).
• Cardiac: Orthopnoea, paroxysmal nocturnal dyspnoea, peripheral oedema, palpitations.
• Tuberculous peritonitis: Chronic fever, night sweats, weight loss, abdominal pain (endemic areas or immunocompromised).

Signs

Abdominal Examination:

• Inspection:
  • Abdominal distension (flanks bulge when supine; "frog-belly" appearance if massive).
  • Everted umbilicus (tense ascites increases intra-abdominal pressure).
  • Dilated superficial veins (caput medusae in portal hypertension, radiating from umbilicus).
  • Striae (rapid distension).
• Palpation:
  • Diffuse tenderness suggests SBP or peritoneal irritation.
  • Hepatomegaly (firm, nodular liver in cirrhosis; smooth, tender in cardiac failure; hard, irregular in metastases).
  • Splenomegaly (portal hypertension).
• Percussion:
  • "Shifting dullness: Sensitive for ≥1500 mL ascites. Technique: percuss from midline to flanks (dullness in flanks); reposition patient to lateral decubitus (dullness shifts to new dependent flank). [21]"
  • "Fluid thrill (fluid wave): Less sensitive than shifting dullness; requires ≥3-4 L. Technique: assistant places ulnar hand edge midline to prevent transmission through fat; examiner taps one flank and palpates impulse at opposite flank. [21]"
  • "Puddle sign (rarely performed): Patient on hands and knees; percuss umbilical region for dullness. Detects ~500 mL but impractical."

Cardiovascular Examination:

• Jugular venous pressure (JVP): Elevated in cardiac ascites (right heart failure, constrictive pericarditis); normal or low in cirrhotic ascites.
• Peripheral oedema: Sacral oedema (if bed-bound), pedal oedema (ambulatory).
• Heart sounds: Muffled (pericardial effusion in constrictive pericarditis), S3 gallop (heart failure).

Respiratory Examination:

• Reduced breath sounds, stony dull percussion at lung bases: Hepatic hydrothorax (right-sided pleural effusion in 85%, bilateral 15%, isolated left less than 1%). [22]
• Tachypnoea: Mechanical splinting from tense ascites.

Stigmata of Chronic Liver Disease:

• Jaundice (scleral icterus, skin), palmar erythema, spider naevi (> 5 above nipple line), leuconychia (white nails, hypoalbuminaemia).
• Gynaecomastia, testicular atrophy (hypogonadism), loss of axillary/pubic hair.
• Hepatic encephalopathy: Asterixis (flapping tremor), confusion, fetor hepaticus (sweet, musty breath).
• Dupuytren's contracture (alcohol-related cirrhosis), parotid enlargement (alcoholism).

Signs by Aetiology:

• Cardiac failure: Elevated JVP, pitting oedema, S3 gallop, hepatomegaly (smooth, tender, pulsatile if tricuspid regurgitation).
• Malignancy: Cachexia, palpable abdominal mass or omental nodularity ("omental caking"), supraclavicular lymphadenopathy (Virchow's node), umbilical nodule (Sister Mary Joseph nodule—periumbilical metastasis).
• Tuberculous peritonitis: Doughy, tender abdomen; ascites often loculated; hepatosplenomegaly.

Red Flags — Immediate Action Required

[!CAUTION] Red Flags — Seek urgent senior review and investigation if:

• Fever (≥38°C), abdominal pain, or tenderness: SBP until proven otherwise. Perform diagnostic paracentesis immediately; commence empirical antibiotics if neutrophils ≥250/mm³. [6,7]
• Worsening hepatic encephalopathy: Grade ≥2 (drowsiness, confusion); may indicate SBP, GI bleeding, electrolyte disturbance, or medication non-compliance.
• Acute kidney injury (AKI): Rising creatinine, oliguria; exclude over-diuresis, hypovolaemia, nephrotoxins, or hepatorenal syndrome. [17]
• Tense ascites with respiratory distress: Large-volume therapeutic paracentesis urgently required.
• Bloody ascites: Haemorrhagic ascites suggests malignancy (especially hepatocellular carcinoma), trauma, or tuberculosis. SAAG and cytology essential.
• Refractory ascites: Ascites unresponsive to maximum diuretics (spironolactone 400 mg + furosemide 160 mg) with dietary sodium restriction, or recurrence despite compliance. Refer for TIPS evaluation or transplant assessment. [8]

---

5. Differential Diagnosis

The differential diagnosis of abdominal distension extends beyond ascites. Once ascites is confirmed, SAAG-based classification guides further evaluation.

Differential Diagnosis of Abdominal Distension

Differential Diagnosis of Ascites by SAAG

Once ascites is confirmed (clinically or radiologically), diagnostic paracentesis is mandatory to calculate SAAG and guide further investigation.

SAAG ≥11 g/L (Portal Hypertension)

SAAG less than 11 g/L (Non-Portal Hypertension)

---

6. Investigations

Diagnostic Paracentesis — Mandatory First-Line Investigation

Indications:

• All new-onset ascites (establish diagnosis, calculate SAAG).
• Any cirrhotic patient with ascites admitted to hospital (exclude SBP, even if asymptomatic). [6,7,9]
• Clinical suspicion of SBP (fever, abdominal pain, encephalopathy, AKI).
• Worsening ascites or lack of response to diuretics.

Contraindications:

• Absolute: None (even coagulopathy or thrombocytopenia are relative).
• Relative: Clinically evident fibrinolysis/DIC (seek expert guidance); cellulitis at puncture site (choose alternative site); distended bowel or organomegaly (USS-guided).

Safety:

• Risk of serious haemorrhage less than 1%, even with INR > 2 or platelets > 40,000/μL. [9]
• Prophylactic transfusion NOT routinely required: No evidence platelets or FFP reduce bleeding risk; may cause volume overload. [9]
• Use small-gauge needle (21-22G); avoid inferior epigastric vessels (lateral to rectus sheath).

Technique:

• Site: Left lower quadrant (LLQ preferred; thinner abdominal wall, less bowel), 2-3 cm medial and superior to anterior superior iliac spine, lateral to rectus sheath. Avoid midline (bladder, bowel adhesions).
• USS guidance: Not mandatory for diagnostic tap but recommended if unclear anatomy, organomegaly, or prior surgery. Mandatory for therapeutic paracentesis.
• Sterile technique: Chlorhexidine prep; local anaesthetic (1% lidocaine); Z-track technique (displace skin before insertion to create tissue seal on withdrawal).
• Aspiration: 30-50 mL sufficient for diagnostic tests; send immediately to lab.

Ascitic Fluid Analysis

SAAG Calculation:

• SAAG = (serum albumin in g/L) - (ascitic fluid albumin in g/L)
• Perform serum albumin on same day as paracentesis.
• SAAG ≥11 g/L: Portal hypertension (97% accuracy). [4]
• SAAG less than 11 g/L: Non-portal causes.

Laboratory Tests

Imaging

Additional Investigations (Selected Cases)

---

7. Classification & Grading

Grading of Ascites Severity

The International Ascites Club classifies ascites severity into three grades based on clinical and imaging findings. [1]

Refractory Ascites

Definition (International Ascites Club): [8]

• Diuretic-resistant ascites: Ascites that cannot be mobilized or early recurrence (≤4 weeks) despite maximum diuretic therapy (spironolactone 400 mg/day + furosemide 160 mg/day) and dietary sodium restriction (less than 2 g/day).
• Diuretic-intractable ascites: Ascites that cannot be mobilized OR early recurrence due to development of diuretic-induced complications (hyponatraemia less than 125 mmol/L, AKI with creatinine rise > 100%, hyperkalaemia > 6 mmol/L, hepatic encephalopathy) preventing effective diuretic dosing.

Prevalence: Approximately 10% of cirrhotic patients with ascites develop refractory ascites. [8]

Prognosis: Median survival 6-12 months without liver transplantation. [8]

Management Options:

1. Serial large-volume paracentesis (LVP) + albumin replacement (8 g per litre drained if > 5 L). [10]
2. Transjugular intrahepatic portosystemic shunt (TIPS): Reduces portal pressure; improves ascites control; survival benefit uncertain; increased encephalopathy risk. [24]
3. Liver transplantation: Definitive treatment; refractory ascites warrants MELD exception points in some jurisdictions.

---

8. Management

Management Algorithm for Cirrhotic Ascites

                NEW ASCITES DIAGNOSED
                         ↓
    ┌────────────────────────────────────────────┐
    │      DIAGNOSTIC PARACENTESIS (Mandatory)   │
    │  Send: Cell count, albumin, culture, ±other│
    └────────────────────────────────────────────┘
                         ↓
    ┌────────────────────────────────────────────┐
    │          CALCULATE SERUM-ASCITES           │
    │          ALBUMIN GRADIENT (SAAG)           │
    ├────────────────────────────────────────────┤
    │  SAAG ≥11 g/L → Portal Hypertension        │
    │                 (Cirrhosis, cardiac, BCS)  │
    │  SAAG less than 11 g/L → Non-portal causes          │
    │                 (Malignancy, TB, pancreas) │
    └────────────────────────────────────────────┘
                         ↓
         ┌───────────────┴───────────────┐
         ↓                               ↓
  SAAG ≥11 g/L                     SAAG less than 11 g/L
  (CIRRHOTIC ASCITES)              (Investigate specific cause:
         ↓                         cytology, ADA, amylase, etc.)
    ┌─────────────────────────────────────────┐
    │  INITIAL MANAGEMENT (All Grades)        │
    ├─────────────────────────────────────────┤
    │  1. Sodium restriction less than 2 g/day (88 mmol)│
    │  2. Spironolactone 100 mg OD            │
    │  3. Add furosemide 40 mg OD if no       │
    │     response after 1 week               │
    │  4. Fluid restriction ONLY if Na less than 125   │
    │  5. Avoid NSAIDs, nephrotoxins          │
    │  6. Alcohol abstinence (if ARLD)        │
    └─────────────────────────────────────────┘
                         ↓
    ┌─────────────────────────────────────────┐
    │  MONITOR RESPONSE                       │
    ├─────────────────────────────────────────┤
    │  - Daily weight (target loss:           │
    │    0.5 kg/day if ascites alone;         │
    │    1 kg/day if peripheral oedema too)   │
    │  - U&Es every 3-5 days initially        │
    │  - Stop diuretics if AKI, severe        │
    │    hyponatraemia (less than 120), hyperkalaemia  │
    └─────────────────────────────────────────┘
                         ↓
         ┌───────────────┴────────────────┐
         ↓                                ↓
    ADEQUATE RESPONSE            INADEQUATE RESPONSE
    (Ascites improving)          (After 1 week)
         ↓                                ↓
    Continue diuretics        ┌───────────────────────────┐
    Monitor weight, U&Es      │ ESCALATE DIURETICS        │
    OGD (variceal screening)  │ Increase proportionally:  │
                              │ Spiro 200/Furo 80         │
                              │ Spiro 300/Furo 120        │
                              │ MAX: Spiro 400/Furo 160   │
                              └───────────────────────────┘
                                         ↓
                    ┌────────────────────┴────────────────────┐
                    ↓                                         ↓
            RESPONSE TO MAX DOSE                    REFRACTORY ASCITES
            Continue diuretics              (No response or diuretic-intractable)
                                                             ↓
                              ┌─────────────────────────────────────────┐
                              │  REFRACTORY ASCITES MANAGEMENT          │
                              ├─────────────────────────────────────────┤
                              │  1. Serial large-volume paracentesis    │
                              │     + albumin (8 g per L if > 5 L drain) │
                              │  2. Consider TIPS (if suitable)         │
                              │  3. Liver transplant evaluation         │
                              │  4. Midodrine + octreotide (off-label)  │
                              └─────────────────────────────────────────┘

Conservative (Non-Pharmacological) Management

Medical Management

Diuretic Therapy

First-Line: Spironolactone (Aldosterone Antagonist)

• Mechanism: Competitive mineralocorticoid receptor antagonist; blocks aldosterone-mediated sodium reabsorption in distal convoluted tubule and collecting duct.
• Starting dose: 100 mg once daily (morning).
• Titration: Increase by 100 mg every 5-7 days if inadequate response; maximum 400 mg/day.
• Monitoring: U&Es every 3-5 days initially (risk hyperkalaemia, especially if baseline K > 5 mmol/L or eGFR less than 60).
• Adverse effects: Hyperkalaemia (10-20%), AKI, painful gynaecomastia (anti-androgen effect; consider amiloride 10-40 mg/day as alternative if intolerable). [5]

Second-Line: Furosemide (Loop Diuretic)

• Mechanism: Inhibits Na-K-2Cl cotransporter in thick ascending limb of loop of Henle; rapid natriuresis.
• Starting dose: 40 mg once daily (morning); add to spironolactone if insufficient response after 1 week monotherapy.
• Titration: Increase proportionally with spironolactone (maintain 100:40 ratio to preserve normokalemia). E.g., spironolactone 200 mg + furosemide 80 mg; maximum spironolactone 400 mg + furosemide 160 mg. [5]
• Monitoring: U&Es (hypokalaemia, hyponatraemia, AKI risk), daily weight.
• Adverse effects: Hypokalaemia (10-15%), hyponatraemia, AKI, ototoxicity (high doses).

Target Weight Loss:

• Ascites alone: 0.5 kg/day (maximum safe peritoneal fluid reabsorption rate ~500 mL/day).
• Ascites + peripheral oedema: 1 kg/day (peripheral oedema mobilizes faster). [5]

When to STOP Diuretics:

• AKI: Creatinine rise > 50% from baseline (hold diuretics, assess volume status, exclude HRS).
• Severe hyponatraemia: Na less than 120 mmol/L (stop diuretics; fluid restriction 1-1.5 L/day; seek specialist input).
• Hyperkalaemia: K > 6 mmol/L (stop spironolactone; furosemide monotherapy temporarily).
• Hepatic encephalopathy: Grade ≥2 (diuretics may worsen encephalopathy via electrolyte disturbance; reduce dose or hold).

Albumin Therapy

Indication 1: Post-Large-Volume Paracentesis (> 5 L)

• Dose: 8 g albumin per litre of ascites drained if > 5 L removed. [10]
• Mechanism: Prevents post-paracentesis circulatory dysfunction (PPCD), characterized by renal impairment, hyponatraemia, rapid ascites re-accumulation, increased mortality.
• Evidence: Meta-analyses demonstrate reduced mortality and HRS incidence vs. no albumin or synthetic colloids. [10]
• Administration: IV 20% albumin infusion post-paracentesis.

Indication 2: Spontaneous Bacterial Peritonitis (SBP)

• Dose: 1.5 g/kg albumin IV at diagnosis, then 1 g/kg on day 3. [7]
• Evidence: RCTs show reduced HRS incidence (10% vs. 33%) and mortality (10% vs. 29%) vs. antibiotics alone, particularly in high-risk patients (creatinine > 88 μmol/L, bilirubin > 68 μmol/L, or blood urea > 30 mg/dL). [7]

Indication 3: Long-Term Albumin in Refractory Ascites (Investigational)

• ANSWER Trial (2018): Weekly albumin 40 g + diuretics improved 18-month survival vs. diuretics alone (38% vs. 27%, p=0.028) in decompensated cirrhosis. [25]
• Current status: Not standard practice outside trial settings; cost-effectiveness debated; consider in highly selected refractory ascites patients.

Therapeutic Paracentesis (Large-Volume Paracentesis, LVP)

Indications:

• Tense ascites (Grade 3) with symptoms (dyspnoea, abdominal discomfort, reduced mobility, anorexia).
• Refractory ascites (serial LVP as bridging to TIPS or transplant).
• Respiratory compromise from ascites.

Technique:

• Site: As per diagnostic paracentesis; USS guidance recommended for large-volume drainage (identify safe window, avoid bowel/vessels).
• Drain to dryness: Complete drainage ("dry tap") superior to partial drainage; faster symptom relief, no increased AKI risk if albumin given. [10]
• Rate: Can drain rapidly (1-2 hours for 10-15 L); no evidence slow drainage reduces complications.
• Albumin replacement: 8 g per litre drained if > 5 L removed (prevents PPCD). [10] If less than 5 L drained, albumin benefit uncertain (some guidelines recommend regardless).
• Post-procedure: Monitor BP (hypotension rare if albumin given), U&Es (next day).

Safety:

• Complications: Haemorrhage (less than 1%), infection (less than 1%), bowel perforation (extremely rare if USS-guided), persistent leak (1-5%; usually resolves; can apply pressure dressing or purse-string suture).
• Coagulopathy NOT a contraindication (see Diagnostic Paracentesis section). [9]

Frequency:

• Repeat as needed for symptom control in refractory ascites (some patients require weekly to monthly LVP indefinitely).

Transjugular Intrahepatic Portosystemic Shunt (TIPS)

Mechanism:

• Interventional radiology procedure creating intrahepatic shunt between portal vein and hepatic vein, bypassing cirrhotic liver; reduces portal pressure (HVPG), decreasing ascites formation.

Indications:

• Refractory ascites requiring frequent LVP (≥3 per month). [24]
• Recurrent variceal bleeding despite endoscopic therapy.
• Hepatic hydrothorax refractory to medical therapy.

Contraindications:

• Absolute: Right heart failure (TIPS increases venous return, precipitates decompensation), severe pulmonary hypertension (mean PAP > 45 mmHg), severe tricuspid regurgitation, polycystic liver disease, uncontrolled sepsis, unrelieved biliary obstruction.
• Relative: Hepatic encephalopathy (TIPS increases risk; 20-30% develop new/worsening encephalopathy post-TIPS), poor liver function (MELD > 18-25 depending on study; higher mortality), hepatocellular carcinoma outside Milan criteria, portal vein thrombosis (technical difficulty).

Efficacy:

• Ascites control: 60-80% achieve complete resolution; ~90% reduce paracentesis frequency. [24]
• Survival: Meta-analyses show improved transplant-free survival vs. LVP in selected refractory ascites patients (HR 0.74, 95% CI 0.58-0.94). [24]
• Encephalopathy risk: 20-30% develop new or worsening encephalopathy; 5-10% refractory.

Post-TIPS Management:

• Continue diuretics (often can reduce dose).
• Monitor for encephalopathy (lactulose, rifaximin if develops).
• TIPS surveillance: Doppler USS every 6-12 months (stenosis occurs in 20-30% bare metal stents; less than 10% covered stents).

Liver Transplantation

Indications:

• Development of ascites in cirrhosis (first decompensation event) warrants transplant evaluation.
• MELD score: Used to prioritize transplant allocation (incorporates creatinine, bilirubin, INR). MELD ≥15 generally considered transplant threshold.
• Refractory ascites: Confers worse prognosis; consider MELD exception points in some jurisdictions.

Outcomes:

• 5-year post-transplant survival: ~75% in appropriately selected patients.

SBP Treatment & Prophylaxis

Empirical Antibiotic Therapy for SBP (ascitic neutrophils ≥250/mm³):

• First-line: Cefotaxime 2 g IV every 8 hours for 5 days. [6,7]
• Alternative: Ceftriaxone 2 g IV once daily (equivalent efficacy, more convenient). [7]
• Oral therapy (if no sepsis, no shock, no encephalopathy, no GI bleeding): Ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 1 g PO three times daily. [7]
• Albumin: 1.5 g/kg IV at diagnosis, 1 g/kg on day 3 (reduces HRS and mortality). [7]
• Duration: 5 days (longer courses no additional benefit).

Secondary Prophylaxis (after SBP episode; prevent recurrence):

• Indefinite antibiotic prophylaxis: Norfloxacin 400 mg PO once daily indefinitely, OR ciprofloxacin 750 mg PO once weekly, OR trimethoprim-sulfamethoxazole 960 mg PO daily. [7]
• Recurrence risk without prophylaxis: 70% at 1 year. [7]
• Efficacy: Secondary prophylaxis reduces recurrence to ~20% at 1 year.

Primary Prophylaxis (prevent first SBP in high-risk patients):

• Indications:
  1. Ascitic fluid protein less than 15 g/L + (Child-Pugh score ≥9 with bilirubin ≥3 mg/dL, OR serum creatinine ≥1.2 mg/dL, OR serum sodium ≤130 mmol/L). [23]
  2. Prior variceal bleeding (independent SBP risk factor).
• Regimen: Norfloxacin 400 mg PO once daily, OR ciprofloxacin, OR trimethoprim-sulfamethoxazole (as per secondary prophylaxis).
• Efficacy: Reduces 1-year SBP probability from 60% to 7-20%, improves survival. [23]

Disposition & Follow-Up

Admit if:

• SBP or suspected infection.
• Tense ascites requiring urgent LVP.
• Acute kidney injury (exclude over-diuresis, HRS).
• Hepatic encephalopathy ≥Grade 2.
• Variceal bleeding.
• First presentation ascites (full work-up, initiate therapy).

Discharge if:

• Stable on diuretics, ascites controlled, no complications.
• Able to perform daily weights at home.
• Dietary sodium restriction education provided.
• Follow-up arranged (Hepatology, GP).

Follow-Up:

• Weekly initially: Weight monitoring, U&Es (adjust diuretics).
• Monthly once stable: Weight, clinical examination, U&Es, LFTs.
• 6-monthly: AFP + liver USS (HCC surveillance), OGD if due (variceal screening/surveillance).
• Transplant evaluation: Refer if MELD ≥15, refractory ascites, or other decompensation.

---

9. Complications of Ascites & Its Management

Immediate Complications

Early Complications (Weeks to Months)

Late Complications (Months to Years)

---

10. Prognosis & Outcomes

Natural History & Survival

The development of ascites fundamentally alters cirrhosis prognosis, signifying decompensation.

Prognostic Factors

Favourable Prognostic Factors:

• First episode ascites (vs. recurrent decompensation).
• Child-Pugh Class A (5-6 points; well-preserved liver function).
• Low MELD score (less than 15).
• Response to diuretics (ascites resolves or markedly improves on spironolactone ± furosemide).
• No SBP, no variceal bleeding, no encephalopathy.
• Normal serum sodium (≥135 mmol/L; hyponatraemia predicts mortality).
• Preserved renal function (creatinine less than 100 μmol/L, eGFR > 60).
• Alcohol abstinence if alcohol-related liver disease (liver function may improve).

Adverse Prognostic Factors:

• Refractory ascites (median survival 6-12 months). [8]
• Hepatorenal syndrome (median survival less than 2 weeks untreated). [17]
• Recurrent SBP (50% 1-year mortality despite antibiotics). [7]
• High MELD score (≥18-20; predicts 3-month mortality).
• Hyponatraemia (Na less than 130 mmol/L; independent mortality predictor).
• Low mean arterial pressure (less than 82 mmHg; circulatory dysfunction).
• Child-Pugh Class C (10-15 points; decompensated cirrhosis).
• Active alcohol use or ongoing hepatic insult.
• Hepatocellular carcinoma (worsens prognosis unless within Milan criteria for transplant).

Prognostic Scoring Systems

Child-Pugh Score (classifies cirrhosis severity):

• Class A (5-6 points): 1-year survival 100%, 2-year survival 85%.
• Class B (7-9 points): 1-year survival 80%, 2-year survival 60%.
• Class C (10-15 points): 1-year survival 45%, 2-year survival 35%.

MELD Score (Model for End-Stage Liver Disease; predicts 3-month mortality, used for transplant allocation):

• Formula: 3.78×ln[bilirubin mg/dL] + 11.2×ln[INR] + 9.57×ln[creatinine mg/dL] + 6.43
• MELD less than 10: 1.9% 3-month mortality.
• MELD 10-19: 6% 3-month mortality.
• MELD 20-29: 19.6% 3-month mortality.
• MELD 30-39: 52.6% 3-month mortality.
• MELD ≥40: 71.3% 3-month mortality.

---

11. Prevention & Screening

Primary Prevention of Ascites

Preventing cirrhosis progression to decompensation (ascites development) is paramount.

Screening for Ascites Complications

---

12. Evidence & Guidelines

Key International Guidelines

1. European Association for the Study of the Liver (EASL) Clinical Practice Guidelines on Decompensated Cirrhosis (2018) [1]

   • Comprehensive guideline on ascites, SBP, hepatorenal syndrome, and hepatic encephalopathy.
   • Recommends diagnostic paracentesis for all new ascites; SAAG calculation; sodium restriction + spironolactone first-line; albumin post-LVP and for SBP.
   • Citation: European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024 [PMID: 29653741]

2. American Association for the Study of Liver Diseases (AASLD) Practice Guidance on Ascites and Hepatorenal Syndrome (2021) [5,17]

   • Evidence-based guidance on diagnosis and management of ascites, refractory ascites, SBP, and HRS.
   • Emphasizes SAAG-based diagnosis, stepwise diuretic therapy, albumin use, TIPS for refractory ascites, and vasoconstrictor therapy for HRS.
   • Citation: Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. doi:10.1002/hep.31884 [PMID: 33942342]

3. International Ascites Club Consensus Definitions (2015) [8]

   • Defines refractory ascites, hepatorenal syndrome, and other cirrhosis complications.
   • Standardizes terminology for research and clinical practice.
   • Citation: Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38(1):258-266. doi:10.1053/jhep.2003.50315 [PMID: 12830009]

Landmark Trials & Key Evidence

Evidence Levels for Key Interventions

---

13. Common Exam Questions & Viva Points

Frequently Asked Questions (MRCP, FRACP, PLAB, AMC)

1. "What is the serum-ascites albumin gradient (SAAG), and how is it interpreted?"

   • SAAG = serum albumin (g/L) - ascitic fluid albumin (g/L), measured on same day.
   • SAAG ≥11 g/L: Portal hypertension (cirrhosis, cardiac ascites, Budd-Chiari, portal vein thrombosis). Accuracy 97%.
   • SAAG less than 11 g/L: Non-portal causes (peritoneal carcinomatosis, tuberculous peritonitis, pancreatic ascites, nephrotic syndrome).
   • SAAG superior to outdated exudate/transudate classification; unaffected by infection or malignancy. [4]

2. "What are the indications for diagnostic paracentesis?"

   • All new-onset ascites (establish diagnosis, calculate SAAG).
   • Any cirrhotic patient with ascites admitted to hospital (exclude SBP, even if asymptomatic). [6,7]
   • Clinical suspicion of SBP (fever, abdominal pain, encephalopathy, AKI).
   • Worsening ascites or lack of response to diuretics.
   • Paracentesis is safe even with coagulopathy (INR > 2, platelets > 40,000/μL). [9]

3. "How is spontaneous bacterial peritonitis (SBP) diagnosed and managed?"

   • Diagnosis: Ascitic fluid neutrophils ≥250/mm³ (on diagnostic paracentesis) without evidence of intra-abdominal surgical source. [6,7]
   • Empirical antibiotics: Cefotaxime 2 g IV q8h (or ceftriaxone 2 g IV daily) for 5 days. [7]
   • Albumin: 1.5 g/kg IV at diagnosis, 1 g/kg on day 3 (reduces HRS and mortality). [7]
   • Secondary prophylaxis: Norfloxacin 400 mg PO daily indefinitely after SBP episode (prevents recurrence). [7]

4. "Outline the stepwise management of cirrhotic ascites."

   • Step 1: Diagnostic paracentesis (confirm SAAG ≥11 g/L, exclude SBP).
   • Step 2: Sodium restriction less than 2 g/day (88 mmol/day).
   • Step 3: Spironolactone 100 mg OD; add furosemide 40 mg OD if inadequate response after 1 week.
   • Step 4: Titrate diuretics proportionally (100:40 ratio) up to max spironolactone 400 mg + furosemide 160 mg.
   • Step 5: Monitor daily weight (target 0.5 kg/day loss if ascites alone, 1 kg/day if oedema present), U&Es every 3-5 days.
   • Step 6: If refractory ascites (unresponsive to max diuretics), serial large-volume paracentesis + albumin, consider TIPS, liver transplant evaluation. [1,5]

5. "What is refractory ascites, and how is it managed?"

   • Definition: Ascites unresponsive to maximum diuretics (spironolactone 400 mg + furosemide 160 mg) with sodium restriction less than 2 g/day, OR recurrence despite compliance, OR diuretic-intractable (complications prevent dose escalation). [8]
   • Prevalence: ~10% of cirrhotic ascites.
   • Management:
     1. Serial large-volume paracentesis (LVP) + albumin 8 g/L drained (if > 5 L).
     2. TIPS (if suitable: MELD less than 18-25, no severe encephalopathy, no right heart failure). [24]
     3. Liver transplant evaluation (refractory ascites worsens prognosis; median survival 6-12 months).
     4. Investigational: Long-term albumin (ANSWER trial), midodrine + octreotide. [25]

6. "What is the role of albumin in ascites management?"

   • Post-LVP: 8 g per litre drained (if > 5 L) prevents post-paracentesis circulatory dysfunction, reduces HRS and mortality. [10]
   • SBP: 1.5 g/kg IV at diagnosis, 1 g/kg on day 3 reduces HRS (10% vs 33%) and mortality (10% vs 29%). [7]
   • HRS-AKI: 1 g/kg day 1, then 20-40 g/day with vasoconstrictors (terlipressin, noradrenaline, or midodrine+octreotide). [17]
   • Long-term albumin: ANSWER trial showed survival benefit (40 g twice weekly); not yet routine practice. [25]

Viva Opening Statements

Viva Point: "Describe your approach to a patient with newly diagnosed ascites."

"Ascites is the pathological accumulation of fluid in the peritoneal cavity. My approach involves four key steps: First, confirm ascites clinically (shifting dullness, fluid thrill) and radiologically (USS). Second, perform diagnostic paracentesis to calculate the serum-ascites albumin gradient (SAAG), which distinguishes portal hypertensive causes (SAAG ≥11 g/L, such as cirrhosis) from non-portal causes (SAAG less than 11 g/L, such as malignancy or tuberculosis) with 97% accuracy. Third, ascitic fluid analysis includes cell count to exclude spontaneous bacterial peritonitis (neutrophils ≥250/mm³), culture, total protein, and additional tests guided by SAAG (cytology if malignancy suspected, ADA if tuberculous peritonitis suspected). Fourth, manage based on aetiology: in cirrhotic ascites, sodium restriction less than 2 g/day plus spironolactone 100 mg daily, escalating with furosemide in a 100:40 ratio as needed. Therapeutic paracentesis with albumin replacement is indicated for tense or refractory ascites. I would also assess for liver transplant candidacy, as ascites marks decompensation with a 50% 2-year mortality."

Viva Point: "What is spontaneous bacterial peritonitis, and how is it managed?"

"Spontaneous bacterial peritonitis (SBP) is bacterial infection of ascitic fluid without an intra-abdominal surgical source, affecting 10-30% of cirrhotic patients with ascites annually. It is diagnosed by ascitic fluid neutrophil count ≥250/mm³ on diagnostic paracentesis. Clinically, patients present with fever, abdominal pain, or encephalopathy, though 30% are asymptomatic, which is why diagnostic paracentesis should be performed on all cirrhotic patients with ascites admitted to hospital. Management involves empirical third-generation cephalosporin therapy—cefotaxime 2 g IV every 8 hours for 5 days—plus intravenous albumin 1.5 g/kg at diagnosis and 1 g/kg on day 3, which reduces hepatorenal syndrome incidence from 33% to 10% and mortality from 29% to 10% based on the Sort 1999 trial. After resolution, secondary prophylaxis with norfloxacin 400 mg daily indefinitely prevents recurrence, which otherwise occurs in 70% at 1 year."

Common Mistakes to Avoid

❌ Mistake 1: Waiting for symptoms before performing diagnostic paracentesis.

• ✅ Correct approach: Paracentesis is mandatory for all new ascites and all cirrhotic patients with ascites admitted to hospital, regardless of symptoms. SBP is asymptomatic in 30% of cases. [6,7]

❌ Mistake 2: Using exudate/transudate classification instead of SAAG.

• ✅ Correct approach: SAAG has replaced the outdated exudate/transudate system. SAAG ≥11 g/L = portal hypertension (97% accuracy). [4]

❌ Mistake 3: Starting furosemide monotherapy for cirrhotic ascites.

• ✅ Correct approach: Spironolactone is first-line (aldosterone antagonism targets primary mechanism). Add furosemide in 100:40 ratio if insufficient response. [5]

❌ Mistake 4: Withholding paracentesis due to coagulopathy (elevated INR, low platelets).

• ✅ Correct approach: Paracentesis is safe even with INR > 2 or platelets > 40,000/μL. Prophylactic FFP or platelet transfusion NOT routinely required. [9]

❌ Mistake 5: Omitting albumin after large-volume paracentesis or in SBP.

• ✅ Correct approach: Albumin 8 g per litre drained (if > 5 L LVP) prevents post-paracentesis circulatory dysfunction. Albumin 1.5 g/kg + 1 g/kg day 3 in SBP reduces HRS and mortality. [7,10]

❌ Mistake 6: Fluid restricting all cirrhotic ascites patients.

• ✅ Correct approach: Fluid restriction ONLY if severe hyponatraemia (Na less than 125 mmol/L). Routine fluid restriction offers no benefit and reduces compliance. [5]

❌ Mistake 7: Failing to calculate SAAG or send ascitic fluid for culture in blood culture bottles.

• ✅ Correct approach: SAAG is diagnostic cornerstone (measure serum and ascitic albumin same day). Inoculate ascitic fluid into blood culture bottles at bedside (increases culture sensitivity from 50% to 80%). [4,6]

---

14. Patient & Layperson Explanation

What is Ascites?

Ascites is a build-up of fluid in your tummy (abdomen). Normally, there is only a tiny amount of fluid in the space around your organs, but in ascites, litres of fluid can accumulate, causing your abdomen to swell.

What Causes Ascites?

The most common cause (75-85%) is cirrhosis (scarring of the liver), usually due to long-term alcohol use, hepatitis B or C virus infection, or fatty liver disease. Other causes include heart problems, cancer spreading to the abdomen, and kidney disease.

When the liver is scarred, blood cannot flow through it easily. This increases pressure in the blood vessels around the liver (portal hypertension), causing fluid to leak into the abdomen. The kidneys also hold on to salt and water, making the problem worse.

Why Does It Matter?

Ascites is a sign that your liver (or heart, or kidneys) is not working properly. It can cause discomfort, difficulty breathing, and increase your risk of serious infections (spontaneous bacterial peritonitis or SBP). If you have cirrhosis and develop ascites, it is important to see a liver specialist, as your condition has progressed and you may need to be considered for a liver transplant in the future.

How is Ascites Diagnosed?

Your doctor will examine your abdomen and may do an ultrasound scan to confirm fluid is present. They will then perform a paracentesis (also called an "ascitic tap"), where a small needle is inserted through the skin into your abdomen to remove a sample of the fluid. This test is very safe and helps determine the cause of the ascites and check for infection.

How is Ascites Treated?

1. Low-Salt Diet You will need to eat less than 2 grams of salt per day. Salt causes your body to hold on to fluid, making ascites worse. Avoid processed foods, crisps, cured meats, and salty sauces. A dietitian can help you plan meals.

2. Water Tablets (Diuretics) You will be given tablets to help your kidneys remove extra salt and water from your body:

• Spironolactone (usually 100 mg once daily to start, increasing if needed).
• Furosemide (often added if spironolactone alone is not enough; usually 40 mg once daily).

You will need regular blood tests to check your kidney function and salt levels. You should weigh yourself daily at home; losing 0.5-1 kg per day is the target.

3. Draining the Fluid (Paracentesis) If you have a large amount of fluid causing breathlessness or discomfort, doctors can drain it using a needle inserted into your abdomen. This provides rapid relief. If more than 5 litres is drained, you will be given albumin (a protein solution) through a drip to prevent complications.

4. Treating the Underlying Cause

• If you have alcohol-related liver disease, stopping alcohol completely is essential. Your liver function may improve.
• If you have hepatitis B or C, antiviral medications can halt liver damage.
• If you have heart failure, treating your heart condition (medications, sometimes procedures) can help.

5. Preventing Infection (SBP) The fluid in your abdomen can become infected (SBP), which is serious. If you develop a fever, tummy pain, or confusion, seek urgent medical help. Some people need to take a daily antibiotic tablet (norfloxacin) to prevent infection, especially if they have had SBP before.

6. Advanced Treatments If ascites keeps coming back despite tablets (called "refractory ascites"), you may need:

• Repeated drainage every few weeks.
• TIPS procedure: A radiologist inserts a tube inside your liver to reduce pressure in the blood vessels; this helps control ascites but has risks (such as confusion).
• Liver transplant: If your liver is very damaged, a liver transplant may be the only long-term solution.

What Should You Watch For?

Seek urgent medical help if you have:

• Fever or abdominal pain (possible infection).
• Confusion or drowsiness (liver or brain problem).
• Difficulty breathing (fluid pressing on lungs).
• Rapid weight gain or swelling worsening despite treatment.
• Reduced urine output (kidney problem).

What is the Outlook?

The outlook depends on the underlying cause. If ascites is due to cirrhosis:

• With treatment (diet, tablets, managing the liver disease), many people live for years.
• If ascites does not respond to treatment, or if you develop complications like infections or kidney problems, the outlook is more serious, and liver transplant evaluation is important.
• Stopping alcohol (if relevant) and taking medications as prescribed significantly improve outcomes.

Your healthcare team (doctors, nurses, dietitians) will work with you to manage ascites and improve your quality of life.

---

15. References

1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. doi:10.1016/j.jhep.2018.03.024

2. Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4(11):1385-1394. doi:10.1016/j.cgh.2006.08.007

3. Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7(1):122-128. doi:10.1002/hep.1840070124

4. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117(3):215-220. doi:10.7326/0003-4819-117-3-215

5. Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048. doi:10.1002/hep.31884

6. Rimola A, García-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol. 2000;32(1):142-153. doi:10.1016/s0168-8278(00)80201-9

7. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403-409. doi:10.1056/NEJM199908053410603

8. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38(1):258-266. doi:10.1053/jhep.2003.50315

9. Pache I, Bilodeau M. Severe haemorrhage following abdominal paracentesis for ascites in patients with liver disease. Aliment Pharmacol Ther. 2005;21(5):525-529. doi:10.1111/j.1365-2036.2005.02387.x

10. Ginès P, Titó L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94(6):1493-1502. doi:10.1016/0016-5085(88)90691-9

11. D'Amico G, Morabito A, D'Amico M, et al. New concepts on the clinical course and stratification of compensated and decompensated cirrhosis. Hepatol Int. 2018;12(Suppl 1):34-43. doi:10.1007/s12072-017-9808-z

12. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-171. doi:10.1016/j.jhep.2018.09.014

13. Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology. 1988;8(5):1104-1109. doi:10.1002/hep.1840080516

14. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43(2 Suppl 1):S121-S131. doi:10.1002/hep.20993

15. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361(13):1279-1290. doi:10.1056/NEJMra0809139

16. Witte CL, Witte MH, Dumont AE. Lymph imbalance in the genesis and perpetuation of the ascites syndrome in hepatic cirrhosis. Gastroenterology. 1980;78(5 Pt 1):1059-1068.

17. Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968-974. doi:10.1016/j.jhep.2014.12.029

18. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007;18(5):945-949. doi:10.1093/annonc/mdl499

19. Riquelme A, Calvo M, Salech F, et al. Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis: a meta-analysis. J Clin Gastroenterol. 2006;40(8):705-710. doi:10.1097/00004836-200609000-00009

20. Varadarajulu S, Rana SS, Bhasin DK. Endoscopic therapy for pancreatic duct leaks and disruptions. Gastrointest Endosc Clin N Am. 2013;23(4):863-892. doi:10.1016/j.giec.2013.06.007

21. Williams JW Jr, Simel DL. The rational clinical examination. Does this patient have ascites? How to divine fluid in the abdomen. JAMA. 1992;267(19):2645-2648.

22. Badillo R, Rockey DC. Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore). 2014;93(3):135-142. doi:10.1097/MD.0000000000000025

23. Fernández J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133(3):818-824. doi:10.1053/j.gastro.2007.06.065

24. Salerno F, Merli M, Riggio O, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004;40(3):629-635. doi:10.1002/hep.20364

25. Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391(10138):2417-2429. doi:10.1016/S0140-6736(18)30840-7

26. Chatzizacharias NA, Bradley JA, Harper S, et al. Successful surgical management of ruptured umbilical hernias in cirrhotic patients. World J Gastroenterol. 2015;21(10):3109-3113. doi:10.3748/wjg.v21.i10.3109

27. Tandon P, Raman M, Mourtzakis M, Merli M. A practical approach to nutritional screening and assessment in cirrhosis. Hepatology. 2017;65(3):1044-1057. doi:10.1002/hep.29003

28. Thursz M, Kamath PS, Mathurin P, et al. Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study. J Hepatol. 2019;70(3):521-530. doi:10.1016/j.jhep.2018.10.041

29. Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66(5):1444-1453. doi:10.1002/hep.29320

30. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-2593. doi:10.1001/jama.2012.144878

31. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65(1):310-335. doi:10.1002/hep.28906

32. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-750. doi:10.1002/hep.29913

33. Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818-828. doi:10.1056/NEJMoa2008290

---

Last Reviewed: 2026-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference only. Clinical decisions must account for individual patient circumstances, local guidelines, and evolving evidence. Always consult appropriate specialists and apply clinical judgment. This content does not replace professional medical advice, diagnosis, or treatment.